Recent

% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

  • ding_king2000 ding_king2000 Apr 30, 2013 8:55 AM Flag

    Total revenue for the first quarter of 2013 was $7.6 million (including product revenue of $5.4 million), compared to $24.2 million (including product revenue of $22.0 million) for the same period in 2012. The decrease in product revenue of $16.6 million was principally due to a change in the contractual basis of Momenta's earned enoxaparin product revenues following the January 2012 launch of a competitor's generic Lovenox(R)

    This is a disaster, imho..

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Try again.

      {{Cash at 3/31/13 (including $20M restricted cash) was $344.2M, and cash-usage guidance for 2013 remains $20-24 per quarter or $80-90M for the year. The one notable clinical change is that the M402 phase-1/2 trial in pancreatic cancer will now include Abraxane + Gemzar as the baseline therapy (rather than Gemzar alone); the timeline for finishing the phase-1 (open-label) portion of the trial has been pushed back to 1H14 from the prior guidance of 1H13.}}

 
MNTA
19.2753+1.0953(+6.02%)12:25 PMEDT